Cargando…

Decision Aids for Preventive Treatment Alternatives for BRCA1/2 Mutation Carriers: a Systematic Review

Introduction Women with a pathogenic BRCA1/2 mutation have a markedly increased lifetime risk of developing breast and/or ovarian cancer. The current preventive treatment alternatives that are offered are an intensified breast cancer screening programme and risk-reducing operations. Before deciding...

Descripción completa

Detalles Bibliográficos
Autores principales: Krassuski, Lisa Marlene, Kautz-Freimuth, Sibylle, Vennedey, Vera, Rhiem, Kerstin, Schmutzler, Rita K., Stock, Stephanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216782/
https://www.ncbi.nlm.nih.gov/pubmed/34168381
http://dx.doi.org/10.1055/a-1326-1792
_version_ 1783710487389667328
author Krassuski, Lisa Marlene
Kautz-Freimuth, Sibylle
Vennedey, Vera
Rhiem, Kerstin
Schmutzler, Rita K.
Stock, Stephanie
author_facet Krassuski, Lisa Marlene
Kautz-Freimuth, Sibylle
Vennedey, Vera
Rhiem, Kerstin
Schmutzler, Rita K.
Stock, Stephanie
author_sort Krassuski, Lisa Marlene
collection PubMed
description Introduction Women with a pathogenic BRCA1/2 mutation have a markedly increased lifetime risk of developing breast and/or ovarian cancer. The current preventive treatment alternatives that are offered are an intensified breast cancer screening programme and risk-reducing operations. Before deciding on one option, medical and personal factors such as life situation and individual preferences must be weighed carefully. Decision aids are used internationally to support BRCA1/2 mutation carriers during their decision-making process. In this study these are analysed structurally for the first time and their applicability to the German context is examined. Material and Methods A systematic literature search in five electronic databases and a manual search were performed. The identified decision aids were evaluated with regard to formal criteria, medical content and quality. The qualitative assessment used the criteria of the International Patient Decision Aid Standards Collaboration (IPDASi v4.0), which examined various dimensions (e.g., information, probabilities, values). Results Twenty decision aids, which were published between 2003 and 2019 in Australia (n = 4), the United Kingdom (n = 3), Canada (n = 2), the Netherlands (n = 2) and the USA (n = 9), were included. Nine focus on BRCA1/2 mutation carriers and eleven include other risk groups. Eighteen include risk-reducing operations as decision options, 14 list screening methods for breast and/or ovarian cancer, and 13 describe the possibility of pharmacological prevention by means of selective oestrogen receptor modulators or aromatase inhibitors. Nine of the 20 decision aids meet fundamental quality criteria (IPDASi v4.0 qualification criteria). Conclusion International decision aids can serve formally as a basis for a German decision aid for BRCA1/2 mutation carriers. Some of them differ markedly in content from the recommendations of German guidelines. Only a few achieve a high quality.
format Online
Article
Text
id pubmed-8216782
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Georg Thieme Verlag KG
record_format MEDLINE/PubMed
spelling pubmed-82167822021-06-23 Decision Aids for Preventive Treatment Alternatives for BRCA1/2 Mutation Carriers: a Systematic Review Krassuski, Lisa Marlene Kautz-Freimuth, Sibylle Vennedey, Vera Rhiem, Kerstin Schmutzler, Rita K. Stock, Stephanie Geburtshilfe Frauenheilkd Introduction Women with a pathogenic BRCA1/2 mutation have a markedly increased lifetime risk of developing breast and/or ovarian cancer. The current preventive treatment alternatives that are offered are an intensified breast cancer screening programme and risk-reducing operations. Before deciding on one option, medical and personal factors such as life situation and individual preferences must be weighed carefully. Decision aids are used internationally to support BRCA1/2 mutation carriers during their decision-making process. In this study these are analysed structurally for the first time and their applicability to the German context is examined. Material and Methods A systematic literature search in five electronic databases and a manual search were performed. The identified decision aids were evaluated with regard to formal criteria, medical content and quality. The qualitative assessment used the criteria of the International Patient Decision Aid Standards Collaboration (IPDASi v4.0), which examined various dimensions (e.g., information, probabilities, values). Results Twenty decision aids, which were published between 2003 and 2019 in Australia (n = 4), the United Kingdom (n = 3), Canada (n = 2), the Netherlands (n = 2) and the USA (n = 9), were included. Nine focus on BRCA1/2 mutation carriers and eleven include other risk groups. Eighteen include risk-reducing operations as decision options, 14 list screening methods for breast and/or ovarian cancer, and 13 describe the possibility of pharmacological prevention by means of selective oestrogen receptor modulators or aromatase inhibitors. Nine of the 20 decision aids meet fundamental quality criteria (IPDASi v4.0 qualification criteria). Conclusion International decision aids can serve formally as a basis for a German decision aid for BRCA1/2 mutation carriers. Some of them differ markedly in content from the recommendations of German guidelines. Only a few achieve a high quality. Georg Thieme Verlag KG 2021-06 2021-06-21 /pmc/articles/PMC8216782/ /pubmed/34168381 http://dx.doi.org/10.1055/a-1326-1792 Text en The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited.
spellingShingle Krassuski, Lisa Marlene
Kautz-Freimuth, Sibylle
Vennedey, Vera
Rhiem, Kerstin
Schmutzler, Rita K.
Stock, Stephanie
Decision Aids for Preventive Treatment Alternatives for BRCA1/2 Mutation Carriers: a Systematic Review
title Decision Aids for Preventive Treatment Alternatives for BRCA1/2 Mutation Carriers: a Systematic Review
title_full Decision Aids for Preventive Treatment Alternatives for BRCA1/2 Mutation Carriers: a Systematic Review
title_fullStr Decision Aids for Preventive Treatment Alternatives for BRCA1/2 Mutation Carriers: a Systematic Review
title_full_unstemmed Decision Aids for Preventive Treatment Alternatives for BRCA1/2 Mutation Carriers: a Systematic Review
title_short Decision Aids for Preventive Treatment Alternatives for BRCA1/2 Mutation Carriers: a Systematic Review
title_sort decision aids for preventive treatment alternatives for brca1/2 mutation carriers: a systematic review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216782/
https://www.ncbi.nlm.nih.gov/pubmed/34168381
http://dx.doi.org/10.1055/a-1326-1792
work_keys_str_mv AT krassuskilisamarlene decisionaidsforpreventivetreatmentalternativesforbrca12mutationcarriersasystematicreview
AT kautzfreimuthsibylle decisionaidsforpreventivetreatmentalternativesforbrca12mutationcarriersasystematicreview
AT vennedeyvera decisionaidsforpreventivetreatmentalternativesforbrca12mutationcarriersasystematicreview
AT rhiemkerstin decisionaidsforpreventivetreatmentalternativesforbrca12mutationcarriersasystematicreview
AT schmutzlerritak decisionaidsforpreventivetreatmentalternativesforbrca12mutationcarriersasystematicreview
AT stockstephanie decisionaidsforpreventivetreatmentalternativesforbrca12mutationcarriersasystematicreview